These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1962681)
21. The fast track toward new AIDS drugs. Long K; Long R Nurse Pract Forum; 1991 Jun; 2(2):80-1. PubMed ID: 1840952 [No Abstract] [Full Text] [Related]
22. Studying new drugs for HCV. Excerpts from the FDA hearing. Huff B GMHC Treat Issues; 2006; 20(8-12):11-4. PubMed ID: 17569164 [No Abstract] [Full Text] [Related]
23. Preface for the COST Action Special Issue. Barea E; Müller J J Inorg Biochem; 2016 Jul; 160():59-60. PubMed ID: 27325582 [No Abstract] [Full Text] [Related]
24. [Biologically active compounds and scientific heritage of Z.V.Ermol'eva]. Shcherbakova EG; Rastunova GA Antibiot Khimioter; 1998; 43(5):23-7. PubMed ID: 9644520 [No Abstract] [Full Text] [Related]
25. Drug treatment in pregnancy. Schneider H Curr Opin Obstet Gynecol; 1994 Feb; 6(1):50-7. PubMed ID: 8180351 [TBL] [Abstract][Full Text] [Related]
26. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. Meredith PA; Elliott HL J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S26-30. PubMed ID: 7609502 [TBL] [Abstract][Full Text] [Related]
27. New drugs--reports of new drugs recently approved by the FDA. Valacyclovir. Shinkai I; Ohta Y Bioorg Med Chem; 1996 Jan; 4(1):1-2. PubMed ID: 8689229 [No Abstract] [Full Text] [Related]
28. Guidelines of the Food and Drug Administration for study of new drugs in human subjects. Crout JR Ann Intern Med; 1978 Nov; 89(5 Pt 2 Suppl):832-4. PubMed ID: 363002 [TBL] [Abstract][Full Text] [Related]
29. Trough/peak ratios for antihypertensive agents. The issues in perspective. Meredith PA Drugs; 1994 Nov; 48(5):662-6. PubMed ID: 7530624 [No Abstract] [Full Text] [Related]
30. New anti-herpes virus drug being tested. Gunby P JAMA; 1980 Apr; 243(13):1315. PubMed ID: 7359688 [No Abstract] [Full Text] [Related]
31. [Several aspects of the treatment of HIV infections]. Costantino M Minerva Pediatr; 1992 May; 44(5):243. PubMed ID: 1620078 [No Abstract] [Full Text] [Related]
32. From the Food and Drug Administration. McClellan MB JAMA; 2002 Nov; 288(17):2112. PubMed ID: 12413360 [No Abstract] [Full Text] [Related]
34. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Sherman KE; Fleischer R; Laessig K; Murray J; Tauber W; Birnkrant D; Hepatology; 2007 Dec; 46(6):2014-20. PubMed ID: 18027878 [No Abstract] [Full Text] [Related]
35. Antisense drugs progressing through product pipelines. Traynor K Am J Health Syst Pharm; 2002 Nov; 59(21):2046-7. PubMed ID: 12434715 [No Abstract] [Full Text] [Related]
36. PDR provides latest Food and Drug Administration-approved dosage guidelines. Mehta M Arch Intern Med; 2001 Nov; 161(21):2622; author reply 2623. PubMed ID: 11718598 [No Abstract] [Full Text] [Related]
37. FDA panel backs Glaxo Wellcome drug for use in treating chronic hepatitis B. Food and Drug Administration. Newsline People AIDS Coalit N Y; 1998; ():32. PubMed ID: 11367504 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic applications of iminosugars: current perspectives and future opportunities. Horne G; Wilson FX Prog Med Chem; 2011; 50():135-76. PubMed ID: 21315930 [No Abstract] [Full Text] [Related]
39. The food and drug administration's certification of antibiotic drugs for human use. Minchew BH Dis Chest; 1967 Sep; 52(3):417-9. PubMed ID: 6072046 [No Abstract] [Full Text] [Related]
40. Food and Drug Administration approves lamivudine for hepatitis B. Front Med Biol Eng; 1999; 9(1):95. PubMed ID: 10354913 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]